. 2005 Mar 1;92(5):799–806. doi: 10.1038/sj.bjc.6602449

Table 3. Initial RT dose and schedule of randomised trials of chemotherapy with RT vs RT alone in locally advanced NPC.

Author	Weekly fractions	Primary tumour dose	Involved nodes dose	Remaining nodal area (Gy)
Neoadjuvant chemotherapy+RT vs RT alone
VUMCA (1996)	5 × 2 Gy d⁻¹	65–70 Gy	65 Gy	50
Hareyama et al (2002)	5 × 2.0 Gy d⁻¹ or4 × 2.2 Gy d⁻¹	66–68 Gy	66–68 Gy	50
Chua et al (1998)	5 × 2 Gy d⁻¹ (n=110) orhypofractionated (n=176)	66–70 Gy (36%)>70–74 Gy (64%)	60–66 Gy (82.5%)>66–76 Gy (17.5%)	60
Ma et al (2001)	5 × 2.0 Gy d⁻¹	68–72 Gy	60–62 Gy	50

Concurrent chemotherapy+RT vs RT alone
Lin et al (2003)	5 × 2.0 Gy d⁻¹ (n=240) orhyperfractionated (n=44)	70–74 Gy	70–74 Gy	50–60
Chan et al (2002, 2004	5 × 2 Gy d⁻¹	66 Gy	N/A	N/A

Adjuvant chemotherapy+RT vs RT alone
Rossi et al (1988)	1.8 Gy d⁻¹ (n=103) orhyperfractionated (n=13)	60–70 Gy	60–70 Gy	50
Chi et al (2002)	5 × 1.8–2.0 Gy d⁻¹	70–72 Gy	70–72 Gy	50

Neoadjuvant and adjuvant chemotherapy+RT vs RT alone
Chan et al (1995)	N/A	66 Gy±boost	58 Gy+7.5 Gy boost	58

Concurrent and adjuvant chemotherapy+RT vs RT alone
Al-Sarraf et al (1998, 2001)	5 × 1.8–2.0 Gy d⁻¹	70 Gy	66–70 Gy	50
Wee et al (2004)	2.0 Gy d⁻¹	70 Gy	N/A	N/A
Lee et al (2004)	5 × 2.0 Gy d⁻¹	66 Gy	66 Gy	N/A
Kwong et al (2004)	4 × 2.5 Gy d⁻¹ to40 Gy then5 × 2.5 Gy d⁻¹ or	62.5 Gy	62.5 Gy	N/A
	5 × 2.0 Gy d⁻¹	68 Gy	66 Gy	N/A

Gy=Grays; d=day; N/A=not applicable; RT=radiotherapy; NPC=nasopharyngeal carcinoma; a(a₁, a₂, a₃)=combined therapy arm, b=radiotherapy alone arm.